2024-09-04 - Analysis Report
## Abott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company developing, manufacturing, and selling a wide range of medical devices, pharmaceuticals, diagnostics, and nutritional products. 

**Performance Analysis:**

**1. Return Rate:**

* ABT's cumulative return is **41.96%**, while the S&P 500 (VOO) has a cumulative return of **89.66%**.
* This indicates ABT has underperformed the S&P 500 by **-47.7%**, which places it at **14.85%** on the relative divergence scale.

**2. Recent Price Movement:**

* **Closing Price:** $113.27
* **5-Day Moving Average:** $112.95
* **20-Day Moving Average:** $110.9
* **60-Day Moving Average:** $106.71

**3. Technical Indicators:**

* **RSI:** 82.52, indicating overbought conditions.
* **PPO:** 0.03, suggesting potential for continued price momentum.
* **Delta_Previous_Relative_Divergence:** -8.38, indicating a recent short-term price decline.
* **Expected_Return:** 27.09%, indicating a maximum estimated return over a 5-year period.

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue    |
|------------|--------|------------|
| 2024-07-31 | 0.74   | 10.38 B$   |
| 2024-05-02 | 0.7    | 9.96 B$   |
| 2023-11-01 | 0.82   | 10.14 B$   |
| 2023-08-03 | 0.79   | 9.98 B$   |
| 2024-07-31 | 0.79   | 9.98 B$   |

* The most recent earnings report (2024-07-31) showed an EPS of 0.74, slightly lower than the expected 0.78. Revenue came in at 10.38 B$, exceeding expectations.
* Abbott has historically shown consistent revenue growth, but earnings per share have been fluctuating.
* The company faces challenges in the competitive healthcare market and is focusing on innovation and expansion into new markets to drive growth. 

**5. Summary Analysis:**

* ABT has underperformed the S&P 500 over the long term, but recent price action suggests potential for short-term gains. 
* Technical indicators suggest an overbought condition, but positive momentum.
* The latest earnings report shows mixed results, with revenue exceeding expectations but EPS falling short.
* Overall, ABT presents a complex situation with potential for both growth and volatility. Further analysis is recommended before making any investment decisions.

**6. Conclusion:** 

Abbott Laboratories remains a large and diversified healthcare company with a solid track record. While recent performance has been subdued compared to the broader market, the company has potential for growth and innovation in the long term. Investors should carefully consider the company's current valuation, future outlook, and overall risk tolerance before making any investment decisions. 
